138 related articles for article (PubMed ID: 15448009)
1. Prognostic significance of TP53 tumor suppressor gene expression and mutations in human osteosarcoma: a meta-analysis.
Pakos EE; Kyzas PA; Ioannidis JP
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6208-14. PubMed ID: 15448009
[TBL] [Abstract][Full Text] [Related]
2. TP53 mutations and outcome in osteosarcoma: a prospective, multicenter study.
Wunder JS; Gokgoz N; Parkes R; Bull SB; Eskandarian S; Davis AM; Beauchamp CP; Conrad EU; Grimer RJ; Healey JH; Malkin D; Mangham DC; Rock MJ; Bell RS; Andrulis IL
J Clin Oncol; 2005 Mar; 23(7):1483-90. PubMed ID: 15735124
[TBL] [Abstract][Full Text] [Related]
3. The association of P-glycoprotein with response to chemotherapy and clinical outcome in patients with osteosarcoma. A meta-analysis.
Pakos EE; Ioannidis JP
Cancer; 2003 Aug; 98(3):581-9. PubMed ID: 12879476
[TBL] [Abstract][Full Text] [Related]
4. A meta-analysis on the association of HER-2 overexpression with prognosis in human osteosarcoma.
Li YG; Geng X
Eur J Cancer Care (Engl); 2010 May; 19(3):313-6. PubMed ID: 19709164
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of TP53 mutations and P53 protein overexpression in supratentorial WHO grade II astrocytomas and oligoastrocytomas.
Peraud A; Kreth FW; Wiestler OD; Kleihues P; Reulen HJ
Clin Cancer Res; 2002 May; 8(5):1117-24. PubMed ID: 12006527
[TBL] [Abstract][Full Text] [Related]
6. Mutations in TP53 are a prognostic factor in colorectal hepatic metastases undergoing surgical resection.
Molleví DG; Serrano T; Ginestà MM; Valls J; Torras J; Navarro M; Ramos E; Germà JR; Jaurrieta E; Moreno V; Figueras J; Capellà G; Villanueva A
Carcinogenesis; 2007 Jun; 28(6):1241-6. PubMed ID: 17259658
[TBL] [Abstract][Full Text] [Related]
7. [Molecular analysis of tumor suppressor genes p16INK4 and TP53 of osteosarcomas in Spanish children].
Patiño García A; Sierrasesúmaga Ariznabarreta L
An Esp Pediatr; 1997 Nov; 47(5):478-82. PubMed ID: 9586287
[TBL] [Abstract][Full Text] [Related]
8. P53 mutation analysis of colorectal liver metastases: relation to actual survival, angiogenic status, and p53 overexpression.
de Jong KP; Gouw AS; Peeters PM; Bulthuis M; Menkema L; Porte RJ; Slooff MJ; van Goor H; van den Berg A
Clin Cancer Res; 2005 Jun; 11(11):4067-73. PubMed ID: 15930341
[TBL] [Abstract][Full Text] [Related]
9. COPS3 amplification and clinical outcome in osteosarcoma.
Yan T; Wunder JS; Gokgoz N; Gill M; Eskandarian S; Parkes RK; Bull SB; Bell RS; Andrulis IL
Cancer; 2007 May; 109(9):1870-6. PubMed ID: 17366602
[TBL] [Abstract][Full Text] [Related]
10. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment.
Russo A; Bazan V; Iacopetta B; Kerr D; Soussi T; Gebbia N;
J Clin Oncol; 2005 Oct; 23(30):7518-28. PubMed ID: 16172461
[TBL] [Abstract][Full Text] [Related]
11. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.
Olivier M; Langerød A; Carrieri P; Bergh J; Klaar S; Eyfjord J; Theillet C; Rodriguez C; Lidereau R; Bièche I; Varley J; Bignon Y; Uhrhammer N; Winqvist R; Jukkola-Vuorinen A; Niederacher D; Kato S; Ishioka C; Hainaut P; Børresen-Dale AL
Clin Cancer Res; 2006 Feb; 12(4):1157-67. PubMed ID: 16489069
[TBL] [Abstract][Full Text] [Related]
12. Germ-line genetic variation of TP53 in osteosarcoma.
Savage SA; Burdett L; Troisi R; Douglass C; Hoover RN; Chanock SJ;
Pediatr Blood Cancer; 2007 Jul; 49(1):28-33. PubMed ID: 17096406
[TBL] [Abstract][Full Text] [Related]
13. CD9 expression is not a prognostic factor in human osteosarcoma.
Kubista B; Erovic BM; Klinger H; Sulzbacher I; Trieb K
Cancer Lett; 2004 Jun; 209(1):105-10. PubMed ID: 15145525
[TBL] [Abstract][Full Text] [Related]
14. Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen.
Bertheau P; Turpin E; Rickman DS; Espié M; de Reyniès A; Feugeas JP; Plassa LF; Soliman H; Varna M; de Roquancourt A; Lehmann-Che J; Beuzard Y; Marty M; Misset JL; Janin A; de Thé H
PLoS Med; 2007 Mar; 4(3):e90. PubMed ID: 17388661
[TBL] [Abstract][Full Text] [Related]
15. Body mass index (BMI) and mutations of tumor suppressor gene p53 (TP53) in patients with urinary bladder cancer.
Ecke TH; Schlechte HH; Gunia S; Lenk SV; Loening SA
Urol Oncol; 2008; 26(5):470-3. PubMed ID: 18367114
[TBL] [Abstract][Full Text] [Related]
16. [Both somatic and germline genetics of the TP53-pathway influence ovarian cancer incidence and survival].
Böhnke A; Jung J; Taubert H; Hauptmann S; Bartel F
Verh Dtsch Ges Pathol; 2007; 91():233-42. PubMed ID: 18314620
[TBL] [Abstract][Full Text] [Related]
17. Prediction of breast cancer prognosis by gene expression profile of TP53 status.
Takahashi S; Moriya T; Ishida T; Shibata H; Sasano H; Ohuchi N; Ishioka C
Cancer Sci; 2008 Feb; 99(2):324-32. PubMed ID: 18271932
[TBL] [Abstract][Full Text] [Related]
18. High resolution melting for mutation scanning of TP53 exons 5-8.
Krypuy M; Ahmed AA; Etemadmoghadam D; Hyland SJ; ; DeFazio A; Fox SB; Brenton JD; Bowtell DD; Dobrovic A
BMC Cancer; 2007 Aug; 7():168. PubMed ID: 17764544
[TBL] [Abstract][Full Text] [Related]
19. TP53 Mutations and Survival in Osteosarcoma Patients: A Meta-Analysis of Published Data.
Chen Z; Guo J; Zhang K; Guo Y
Dis Markers; 2016; 2016():4639575. PubMed ID: 27239089
[TBL] [Abstract][Full Text] [Related]
20. Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients.
Westra JL; Schaapveld M; Hollema H; de Boer JP; Kraak MM; de Jong D; ter Elst A; Mulder NH; Buys CH; Hofstra RM; Plukker JT
J Clin Oncol; 2005 Aug; 23(24):5635-43. PubMed ID: 16110022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
